JP6947720B2 - Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法 - Google Patents

Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法 Download PDF

Info

Publication number
JP6947720B2
JP6947720B2 JP2018512945A JP2018512945A JP6947720B2 JP 6947720 B2 JP6947720 B2 JP 6947720B2 JP 2018512945 A JP2018512945 A JP 2018512945A JP 2018512945 A JP2018512945 A JP 2018512945A JP 6947720 B2 JP6947720 B2 JP 6947720B2
Authority
JP
Japan
Prior art keywords
allogeneic
cells
cell population
specific embodiment
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018512945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530534A5 (https=
JP2018530534A (ja
Inventor
コエフネ グエンサー
コエフネ グエンサー
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2018530534A publication Critical patent/JP2018530534A/ja
Publication of JP2018530534A5 publication Critical patent/JP2018530534A5/ja
Application granted granted Critical
Publication of JP6947720B2 publication Critical patent/JP6947720B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018512945A 2015-09-10 2016-09-09 Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法 Expired - Fee Related JP6947720B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US62/216,525 2015-09-10
US201562220641P 2015-09-18 2015-09-18
US62/220,641 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (3)

Publication Number Publication Date
JP2018530534A JP2018530534A (ja) 2018-10-18
JP2018530534A5 JP2018530534A5 (https=) 2019-11-28
JP6947720B2 true JP6947720B2 (ja) 2021-10-13

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512945A Expired - Fee Related JP6947720B2 (ja) 2015-09-10 2016-09-09 Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法

Country Status (14)

Country Link
US (1) US20190381098A1 (https=)
EP (1) EP3347028A1 (https=)
JP (1) JP6947720B2 (https=)
KR (1) KR20180048992A (https=)
CN (1) CN108348552A (https=)
AU (1) AU2016320877A1 (https=)
CA (1) CA2997757A1 (https=)
HK (1) HK1257882A1 (https=)
IL (1) IL257929B2 (https=)
MX (1) MX395106B (https=)
RU (1) RU2743381C2 (https=)
TW (1) TWI759270B (https=)
WO (1) WO2017044678A1 (https=)
ZA (1) ZA201801656B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217203A1 (en) 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ATE399179T1 (de) * 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CA2861206C (en) * 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
CN108348552A (zh) 2018-07-31
TWI759270B (zh) 2022-04-01
IL257929B1 (en) 2024-02-01
WO2017044678A1 (en) 2017-03-16
HK1257882A1 (zh) 2019-11-01
IL257929B2 (en) 2024-06-01
EP3347028A1 (en) 2018-07-18
US20190381098A1 (en) 2019-12-19
ZA201801656B (en) 2022-12-21
TW201714619A (zh) 2017-05-01
RU2018112526A (ru) 2019-10-10
KR20180048992A (ko) 2018-05-10
JP2018530534A (ja) 2018-10-18
RU2743381C2 (ru) 2021-02-17
MX395106B (es) 2025-03-21
IL257929A (en) 2018-05-31
CA2997757A1 (en) 2017-03-16
AU2016320877A1 (en) 2018-04-19
MX2018002816A (es) 2018-06-08
RU2018112526A3 (https=) 2020-01-31

Similar Documents

Publication Publication Date Title
US20230002730A1 (en) Improved targeted t-cell therapy
Handlos Grauslund et al. Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic myeloproliferative neoplasms
JP6947720B2 (ja) Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法
KR20080098066A (ko) 림프구 제거제를 ｃｔｌ 및 사이토카인과 결합한 암 치료
JP2008521406A (ja) 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法
JP2010516772A (ja) 免疫機能を調節する方法
US20210213066A1 (en) Improved cell therapy compositions for hematopoietic stem cell transplant patients
AU2023221021B2 (en) Compositions and methods for antigen-specific t cell expansion
EP3468585A2 (en) Calr and jak2 vaccine compositions
CA3126066A1 (en) Ex vivo activated t-lymphocytic compositions and methods of using the same
JP6811710B2 (ja) トリプトファン２，３−ジオキシゲナーゼまたはそのフラグメントを含むワクチン組成物
Tanaka et al. Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome
Ferulli et al. Generation of donor-derived Wilms tumor antigen 1–specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study
US20160375060A1 (en) Methods of Treating Glioblastoma Multiforme by T Cell Therapy
US20240400992A1 (en) Compositions and methods for antigen-specific t cell expansion
Tentori et al. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL)
JP7437444B2 (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
JP2023099685A (ja) 養子免疫療法における腫瘍フレアを管理する方法
HK40050731A (en) Improved targeted t-cell therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210916

R150 Certificate of patent or registration of utility model

Ref document number: 6947720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees